FDA Approves Innovative Cream to Treat Chronic Hand Eczema
The FDA has approved the first prescription cream for treating chronic hand eczema, offering new hope to millions affected by this persistent skin condition. Learn about this breakthrough treatment and its potential impact.
The U.S. Food and Drug Administration (FDA) has approved the first topical cream specifically designed to treat chronic hand eczema (CHE), a persistent and often debilitating skin condition. CHE is characterized by redness, itching, cracking, and inflammation on the hands and wrists, affecting about 10% of the U.S. population. Unlike atopic dermatitis, which is more common, CHE tends to be rarer but significantly impacts quality of life, particularly in individuals exposed to irritants or allergens occupationally, such as those working in cleaning, healthcare, or hairstyling industries.
The newly approved medication, Anzupgo (delgocitinib), is intended for adults with moderate-to-severe CHE who cannot or do not respond well to topical steroids. It functions by inhibiting JAK enzymes, which are involved in the inflammatory processes that trigger eczema flare-ups.
This treatment offers hope for many patients, as current options were limited and often ineffective. Studies prior to approval demonstrated that patients using Anzupgo experienced notably improved symptoms compared to placebo. Importantly, the cream does not carry the boxed warnings associated with other JAK inhibitors, making it a safer option.
Experts emphasize the significance of this approval. Dr. Linda Stein Gold from Henry Ford Health expressed optimism, citing the considerable burden CHE imposes on sufferers. Kristin Belleson, CEO of the National Eczema Association, highlighted that this development provides new hope for those whose daily lives are disrupted by the disease.
Internationally, Anzupgo has already been approved in regions including the European Union, United Kingdom, Switzerland, and the United Arab Emirates. Its availability in the U.S. marks a pivotal step in advancing treatment options for chronic hand eczema.
This milestone reflects ongoing efforts to address difficult-to-treat skin conditions and improve patient outcomes, especially for those facing persistent and recurrent symptoms.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Lung Cancer Alters Immune Cell Development in Bone Marrow, Impairing the Body's Defense Mechanisms
New research uncovers how lung tumors reprogram immune cells in the bone marrow, weakening the body's defenses and opening new avenues for targeted therapies in lung cancer treatment.
California Advances Legislation to Eliminate PFAS 'Forever Chemicals' from Cookware and Household Products
California is enacting legislation to phase out PFAS 'forever chemicals' from cookware, cleaning products, and household items to protect public health and the environment. The bill aims to reduce exposure to harmful chemicals linked to serious health issues.
US Sees Slight Increase in Measles Cases as New Outbreak Reported in Colorado
Recent CDC data shows a slight rise in measles cases across the U.S., with new outbreaks in Colorado and Texas highlighting the importance of vaccination and vigilance against this highly contagious virus.
Fathers Less Likely to Engage in Important Conversations About Sex with Their Children
A new study reveals that mothers are more likely than fathers to discuss sex and relationships with their children, highlighting the need for greater parental support to foster open conversations about safe and healthy sexuality in families.